StemCell Therapy

New York, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Europe Cartilage Degeneration Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Procedure Type ; Application ; and End User and Country Regional Analysis and Market Forecasts by Procedure Type, Application and End User" - https://www.reportlinker.com/p05978846/?utm_source=GNW However, high cost of cartilage therapies and lack of reimbursement scenario are the factors restraining the growth of the market in this region.

Nevertheless, the growing number of product approvals and rising emphasis on regenerative medicines are likely to fuel the growth of the Europe cartilage degeneration market during the forecast period.Degeneration of cartilage leads to pain and chronic inflammation in joints of a human body.Furthermore, damaged cartilage can potentially influence the quality of a patients life.

Continuous research and developments are innovating new techniques and methodologies to deal with damaged cartilages. A few of these techniques comprise joint replacement, cell therapies, and chondroplasty.

Companies in the cartilage degeneration market are undertaking various R&D activities to introduce more innovative products. For instance, in September 2013, OligoMedic, Inc., a global designer, manufacturer, and distributor of osteoarthritis products, launched its CE mark injectable implant JointRep for the treatment of cartilage articular joint defect. Also, the new cartilage therapies are enabling the adoption of advanced cell technologies, which are, in turn, strengthening the procedural outcomes. Furthermore, in May 2017, Co.DON AG got European Medicines Agency (EMA) approval for its Spherox, a knee cartilage repair product for the treatment of symptomatic articular cartilage defects in femoral condyle and patella

The players operating in the cartilage degeneration market are focusing on establishing collaborations and partnerships for the development of advanced products with increasing procedural efficiency. For instance, in October 2018, Gelmetix, a UK-based player, and Stemmatters, a Portuguese regenerative medicine company, entered into a strategic partnership for the innovation and development of an advanced knee cartilage repair device. hus, the increasing number of product approvals, developments, advanced technologies, and strategic activities are projected to offer lucrative opportunities for the growth of the market.

The European economy is severely affected due to the exponential rise in the number of COVID-19 patients in this region.The Medical Device Regulation (MDR) requires manufacturers to conduct Post Market Clinical Follow-Up (PMCF) studies to demonstrate the continued safety and performance of their devices.

This is expected to impact the product launch and ongoing clinical trials of medical devices, thereby hampering the sales and market growth. Also, disrupted supply chains, extended lockdowns, and canceling of other medical procedures have adversely affected the growth of the cartilage degeneration market in Europe.The knee segment accounted for the largest share of the market in 2019.The growth of this segment is attributed to the increasing prevalence of knee injuries.

For instance, according to a study publishedbased on NCBI dataon an online newspaper, one in four adults suffer from chronic knee pain in this region. Moreover, the prevalence of knee pain has witnessed a massive growth of around 40.0% during the past 4 decades. Furthermore, the increasing awareness of benefits provided by cartilage repair is anticipated to drive the growth of the knee segment.

The major secondary sources associated with the Europe cartilage degeneration market report are the World Health Organization (WHO), British Journal of Sports Medicine, European Society of Sports Traumatology, Knee Surgery, Arthroscopy (ESSKA), Organization for Economic Cooperation and Development (OECD), and others.Read the full report: https://www.reportlinker.com/p05978846/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Go here to read the rest:
Europe Cartilage Degeneration Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Procedure Type ; Application ; and End User and...

VALENCIA, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today it plans to release its first quarter 2021 financial results after the market closes on Wednesday, November 11, 2020. In conjunction with such release, the Company plans to host a conference call and webcast that day at 1:30 p.m. Pacific time / 4:30 p.m. Eastern time to discuss its financial results and recent highlights.

Interested parties may access the live call via telephone by dialing (833) 614-1538 for domestic callers or (706) 634-6548 for international callers, using conference ID: 2688929. The live webinar for the call may be accessed by visiting the Events section of the Company's website at ir.avitamedical.com. A replay of the webinar will be available on the Companys website shortly after the conclusion of the call.

Authorized for release by the Chief Executive Officer of AVITA Therapeutics, Inc.

ABOUT AVITA THERAPEUTICS, INC.AVITA Therapeutics is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Therapeutics patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patients own skin. The medical devices work by preparing a RES REGENERATIVE EPIDERMAL SUSPENSION, an autologous suspension comprised of the patients skin cells necessary to regenerate natural healthy epidermis. This autologous suspension is then sprayed onto the areas of the patient requiring treatment.

AVITA Therapeutics first U.S. product, the RECELL System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018. The RECELL System is indicated for use in the treatment of acute thermal burns in patients 18 years and older. The RECELL System is used to prepare Spray-On Skin Cells using a small amount of a patients own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from randomized, controlled clinical trials conducted at major U.S. burn centers and real-world use in more than 8,000 patients globally, reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings. Healthcare professionals should read the INSTRUCTIONS FOR USE - RECELL Autologous Cell Harvesting Device (https://recellsystem.com/) for a full description of indications for use and important safety information including contraindications, warnings and precautions.

In international markets, our products are marketed under the RECELL System brand to promote skin healing in a wide range of applications including burns, chronic wounds and aesthetics. The RECELL System is TGA-registered in Australia and received CE-mark approval in Europe.To learn more, visit http://www.avitamedical.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTSThis letter includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as anticipate, expect, intend, could, may, will, believe, estimate, look forward, forecast, goal, target, project, continue, outlook, guidance, future, other words of similar meaning and the use of future dates. Forward-looking statements in this letter include, but are not limited to, statements concerning, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth in our business, and our ability to achieve our key strategic, operational and financial goal. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward- looking statement contained in this letter is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the timing of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, economic or political conditions outside of the companys control. Investors should not place considerable reliance on the forward-looking statements contained in this letter. Investors are encouraged to read our publicly available filings for a discussion of these and other risks and uncertainties. The forward-looking statements in this letter speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements.

FOR FURTHER INFORMATION:

See the rest here:
AVITA Therapeutics to Announce First Quarter 2021 Financial Results - GlobeNewswire

A new USC-led study suggests a change to the developmental -- and evolutionary -- story of the pituitary gland.

The pea-sized gland, nestled at the base of the brain, produces hormones that drive growth, aggression, sexual development and reproduction. For decades, the front lobe of the pituitary -- where the hormones are made -- was thought to be an evolutionary development that arose in vertebrates, along with the ear, the nose and the lens of the eye.

The widely accepted "new head hypothesis" holds that all of these body parts derive from a particular type of embryonic structure located in the ectoderm, or outermost layer of an embryo. Meanwhile, animals that have spinal cords but lack backbones, understood to represent an earlier evolutionary step, have a pituitary-like structure previously thought to have a distinct origin in the innermost embryonic layer, or endoderm.

In a paper published today in Science, USC researchers present evidence that, in some vertebrates, the endoderm also forms part of the pituitary's front lobe -- an idea that has been the subject of scientific controversy dating back more than 100 years. Findings from the study, which was supported by a major grant from the National Institutes of Health, suggest that the gland may have a longer evolutionary history than previously thought.

"We revisited very old observations with cutting-edge technology that proves this idea that there is an endodermal contribution to the pituitary," said senior author Gage Crump, professor of stem cell and regenerative medicine at the Keck School of Medicine of USC. "Our work revises ideas about what kind of embryonic structure the pituitary is, and when it first evolved."Developmental detective work

Crump and his colleagues studied zebrafish, a species useful as a lab model in part because their development is an open book to researchers; eggs are fertilized externally and embryos are nearly see-through. The research team used new lab methods of their own invention to label the zebrafish's embryonic cells and follow the cells that descended from them through adulthood.

Additionally, they used time-lapse imaging with a powerful microscope and single-cell RNA sequencing. That latter technology is related to DNA sequencing, but instead of characterizing the entire genetic code, it reveals only the genes that are expressed, and in what quantities, for each of thousands of cells at a time -- a powerful way of understanding the nature of the cells being studied.

In a series of experiments with time-lapse imaging of zebrafish embryos, the team documented Rathke's pouch, a structure from the outer layer previously believed to be the sole source of the pituitary's front lobe, fusing with Seessel's pouch, a structure from the inner layer. Their observations indicate that the endoderm was responsible for about 20 percent of the cells in the front lobe of the pituitary.

Another experiment tracking the fate of embryonic cells into adult zebrafish showed a mixture of ectodermally and endodermally derived cells in the pituitary. Delving into gene expression with RNA sequencing, the scientists found that cells from the inner endoderm layer ended up differentiating into all of the major types of hormone-producing cells in the pituitary. Furthermore, in genetically manipulated zebrafish embryos that lacked the ectodermal component , endodermal cells could form a pituitary-like structure on their own, albeit much smaller than the normal pituitary.

Taken together, these investigations clearly demonstrate an endodermal contribution to the zebrafish pituitary. This unexpected revelation suggests that the quasi-pituitary seen in certain more-primal nonvertebrate animals -- undersea creatures that are strange and largely obscure -- may have survived, in a form, among at least some of their backbone-bearing evolutionary descendants.

Crump, who also is the founding director of USC's PhD Program in Development, Stem Cells, and Regenerative Medicine, cautions that it remains to be seen whether the vestige endures in humans.

"It may be that fish retain this ancestral feature, but humans have lost it," he said. "We can see the pituitary is not a brand-new vertebrate structure like the nose or ear or lens, but instead was already present before vertebrates and subsequently incorporated new ectoderm contributions. By capturing this evolutionary relic in zebrafish, we have resolved the mystery of where the pituitary came from."

An old idea that came back around (surprisingly)

As far back as the mid-1910s, anatomists had reported that Rathke's pouch was closely associated with Seessel's pouch. Rathke's pouch has long been understood as the source of the pituitary's endocrine component. By contrast, the fate and purpose of Seessel's pouch has remained a mystery -- until today.

For researchers in the early 20th century (and more or less ever since), there were no good ways to further explore the relation between the two embryonic structures, and thus the possibility of an endodermal contribution to the pituitary. Hotly debated at first, the topic eventually faded into more of a historical curiosity.

Fortunately, first author Peter Fabian, a postdoctoral researcher at the Keck School, was well-versed in this precedent. While trying out one of those new techniques for labeling and tracking embryonic cells, developed by collaborators at Sanford Burnham Prebys Medical Discovery Institute, he noticed endodermal cells in the pituitary. A light bulb went off in his head.

"It was a serendipitous discovery," Crump said. "We're interested in the endoderm in general, but we hadn't set out to study the pituitary. Because this was such an unexpected observation, we really had to prove it with multiple lines of investigation."

Reference: Fabian P, Tseng KC, Smeeton J, et al.Lineage analysis reveals an endodermal contribution to the vertebrate pituitary.Science. 2020;370(6515)463-467. doi:10.1126/science.aba4767

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

See the original post:
A New Piece Added to the Pituitary Gland Puzzle Revises Evolutionary History - Technology Networks

Despite the ethical questions, the field of stem cell research has not slowed particularly within the field of regenerative medicine where the potential for cellular regeneration to kickstart the body's repair mechanism is huge.

But is it as simple as gathering stem cells, putting them into the human body and seeing how things go?

First lets understand the balance within our bodies. Take for example bones, made up by the balance of two types of cell, osteoblasts (builders) and oesteoclasts (dissolvers).

If the body has excess osteoblasts it can lead to abnormal bone growth such as bunions through to Pagets disease. And too many osteoclast cells can lead to bone degeneration conditions such as osteoporosis. Stem cells as the natural building blocks of the body could be used to tell the existing cells how they should be acting to get the balance back and avoid these issues.

While in principle this sounds good, when it comes to degenerative diseases such as Parkinsons, multiple sclerosis, neurodegeneration and cancer, these are complex conditions where imbalances in cell development and chronic inflammation need a more detailed and complete "message" to resolve these issues.

In short, and in keeping with the theme of the US election, rather than rely on multiple random and chaotic tweets from the President, what is required is a more detailed email explaining what each cell should be doing to ensure a harmonious operating environment.

In the 1990s researchers identified that exosomes that secrete naturally from cells were not nanoparcel debris as first thought. Rather, exosomes are bioactive and have the specialised function of carrying messages to other cells in the body instructing them on how they should act.

So if exosomes could be harvested and then delivered to the specific area of the body that needs them, they could aid the bodys healing process.

Excitingly there is a listed Australian company at the forefront of this field of work. Exopharm is the owner of proprietary manufacturing technology called LEAP, which performs the exosome extraction and purification process.

The technology created by the company's chief executive, Ian Dixon, is designed to complete the purification process and facilitate the mass production of pharmaceutical-grade exosomes.

The company has candidates in testing and development, ranging from wound healing to curing dry age-related macular degeneration. Further, it recently signed exclusive IP agreements for the delivery of engineered extracellular vesicles (EEV) which can be designed to carry specific cargos to target particular cells or tissue to cure illnesses.

From an investment perspective, the exciting thing that Exopharm offers is the potential for numerous products to be commercialised using its manufacturing process. It will seek licensing arrangements and partnerships with other parties to deliver their drugs at scale using Exopharm technology

Dixon is supported by a team with experience from big pharma, including Alison Mew, previously a senior manager at CSL and now director of manufacturing and development at Exopharm.

While all biotech firms at the pre-revenue stages carry risks, specifically regulatory and financial, in the case of the latter this is somewhat mitigated for Exopharm as it seeks a model where there are upfront licensing payments for the early stage work with the potential for milestone payments and royalties in the longer term.

While this field of study may seem like science fiction, it is actively pursued in laboratories and discussed in medical journals all over the world, with large pharma refocusing their stem cell work to accommodate the development of exosomes.

Underpinned by the size of the global regenerative medicine market estimated at $US100 billlion ($141 billion) per annum and growing, the prospects for this innovative world leader look positive.

Disclaimer: Spotee and/or its directors, employees, representatives and associates hold an interest in Exopharm.

See more here:
Ways to cash in on regenerative medicine - The Australian Financial Review

The Global Regenerative Medicine Products for Covid-19 2020 Market Research Report is a professional and in-depth study on the current state of Regenerative Medicine Products for Covid-19 Market.

This report studies the Regenerative Medicine Products for Covid-19 market with many aspects of the industry like the market size, market status, market trends and forecast, the report also provides brief information of the competitors and the specific growth opportunities with key market drivers. Find the complete Regenerative Medicine Products for Covid-19 market analysis segmented by companies, region, type and applications in the report.

New vendors in the market are facing tough competition from established international vendors as they struggle with technological innovations, reliability and quality issues. The report will answer questions about the current market developments and the scope of competition, opportunity cost and more.

Request Sample Report @ https://chronicalmarketresearch.com/request-for-sample-report/26169

The report discusses the various types of solutions for Regenerative Medicine Products for Covid-19 Market. While the regions considered in the scope of the report include North America, Europe, and various others. The study also emphasizes on how rising digital security threats is changing the market scenario.

Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.

This report focuses on the global Regenerative Medicine Products for Covid-19 status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Regenerative Medicine Products for Covid-19 development in United States, Europe, China, Japan, Southeast Asia, India, and Central & South America.

Key Players:

The Key manufacturers that are operating in the global Regenerative Medicine Products market are:

Acelity

DePuy Synthes

Medtronic

ZimmerBiomet

Stryker

MiMedx Group

Organogenesis

UniQure

Cellular Dynamics International

Osiris Therapeutics

Vcanbio

Gamida Cell

Golden Meditech

Cytori Therapeutics

Celgene

Vericel Corporation

Guanhao Biotech

Mesoblast

Stemcell Technologes

Bellicum Pharmaceuticals

Competitive Landscape

The Regenerative Medicine Products for Covid-19 market is a comprehensive report which offers a meticulous overview of the market share, size, trends, demand, product analysis, application analysis, regional outlook, competitive strategies, forecasts, and strategies impacting the Regenerative Medicine Products for Covid-19 Industry. The report includes a detailed analysis of the market competitive landscape, with the help of detailed business profiles, SWOT analysis, project feasibility analysis, and several other details about the key companies operating in the market.

Request Discount About This Report @ https://chronicalmarketresearch.com/discount-request-on-report/26169

The study objectives of this report are:

To study and forecast the market size of Regenerative Medicine Products for Covid-19 in global market.

To analyze the global key players, SWOT analysis, value and global market share for top players.

To define, describe and forecast the market by type, end use and region.

To analyze and compare the market status and forecast among global major regions.

To analyze the global key regions market potential and advantage, opportunity and challenge, restraints and risks.

To identify significant trends and factors driving or inhibiting the market growth.

To analyze the opportunities in the market for stakeholders by identifying the high growth segments.

To strategically analyze each submarket with respect to individual growth trend and their contribution to the market

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

To strategically profile the key players and comprehensively analyze their growth strategies.

Following are the segments covered by the report are:

Cell Therapy

Tissue Engineering

Biomaterial

Others

By Application:

Dermatology

Cardiovascular

CNS

Orthopedic

Others

The Regenerative Medicine Products for Covid-19 market research report completely covers the vital statistics of the capacity, production, value, cost/profit, supply/demand import/export, further divided by company and country, and by application/type for best possible updated data representation in the figures, tables, pie chart, and graphs. These data representations provide predictive data regarding the future estimations for convincing market growth. The detailed and comprehensive knowledge about our publishers makes us out of the box in case of market analysis.

Key questions answered in this report

What will the market size be in 2026 and what will the growth rate be?

What are the key market trends?

What is driving this market?

What are the challenges to market growth?

Who are the key vendors in this market space?

What are the market opportunities and threats faced by the key vendors?

What are the strengths and weaknesses of the key vendors?

Request For Customization About This Report @ https://chronicalmarketresearch.com/request-for-customization/26169

Table of Contents

Chapter 1: Global Regenerative Medicine Products for Covid-19 Market Overview

Chapter 2: Regenerative Medicine Products for Covid-19 Market Data Analysis

Chapter 3: Regenerative Medicine Products for Covid-19 Technical Data Analysis

Chapter 4: Regenerative Medicine Products for Covid-19 Government Policy and News

Chapter 5: Global Regenerative Medicine Products for Covid-19 Market Manufacturing Process and Cost Structure

Chapter 6: Regenerative Medicine Products for Covid-19 Productions Supply Sales Demand Market Status and Forecast

Chapter 7: Regenerative Medicine Products for Covid-19 Key Manufacturers

Chapter 8: Up and Down Stream Industry Analysis

Chapter 9: Marketing Strategy -Regenerative Medicine Products for Covid-19 Analysis

Chapter 10: Regenerative Medicine Products for Covid-19 Development Trend Analysis

Chapter 11: Global Regenerative Medicine Products for Covid-19 Market New Project Investment Feasibility Analysis

Contact Us

Chronical Market Research,

4004 W Lake Sammamish,

Pkway B9 Redmond,

WA 98052 United States.

Tel: +44 115 888 3028

Web: http://www.chronicalmarketresearch.com

About Us

At Chronical Market Research, we understand that the research we provide is only as good as the outcome it inspires. These reports are generated by well-renowned publishers on the basis of the data acquired from an extensive research and credible business statistics. Thats why we are proud to provide the widest range of research products, multilingual 24/7 customer support and dedicated custom research services to deliver the insights you need to achieve your goals. Take a look at few of our aspects that makes Chronical Market Research an asset to your business.

Follow this link:
Regenerative Medicine Products Market Shares, Strategies and Forecast Worldwide, 2020 to 2027 - TechnoWeekly

Funding will help fight cancer and blood disorders and address environmental and agricultural challenges

OTTAWA, ON, Oct. 26, 2020 /CNW/ - As the Government of Canada focuses on responding to the challenges of COVID-19, the importance of investing in science and research is clearer than ever. These investments allow researchers to produce the breakthroughs that improve our daily lives, from delivering cutting-edge therapeutics for treating diseases and chronic conditions to developing new technologies that will help Canadian farmers better protect their crops and livestock.

Today, William Amos, Parliamentary Secretary to the Minister of Innovation, Science and Industry (Science), on behalf of the Honourable Navdeep Bains, Minister of Innovation, Science and Industry, announced an investment of more than $20 million to support advances in stem cell and regenerative medicine and support genomics research.

Today's investments include:

Quotes

"The Government of Canada is proud to support Canada's world-leading stem cell and genomics research community. Today's investment has the potential to save lives and come up with new ways of solving environmental and agricultural challenges. This is Canadian science and innovation in action." William Amos, Parliamentary Secretary to the Minister of Innovation, Science and Industry (Science)

"The health and safety of Canadians remains the government's top priority, and the COVID-19 pandemic has illustrated the continued importance of investing in science and research. I would like to extend my congratulations and gratitude to today's recipients, who continue to work so tirelessly to improve the lives of Canadians. The Government of Canada is committed to supporting science and research, which has far-reaching impacts on Canadians' health and day-to-day lives." The Honourable Navdeep Bains, Minister of Innovation, Science, and Industry

"The projects the Stem Cell Network is funding underscore the depth, breadth and innovation of this highly diverse and collaborative community. Thanks to the continued, long-term funding of the Government of Canada, we will continue to deliver leading-edge and viable stem cellbased therapeutics to treat serious illnesses and chronic diseases, for the benefit of all Canadians." Dr. Michael Rudnicki, O.C., FRS, FRSC, Scientific Director & CEO, Stem Cell Network

"Research will be a key driver of Canada's economic recovery and long-term prosperity. Investments in leading genomics research and technology will support the development of sustainable agriculture, more resilient food systems, healthier communities and a greener resource sector. Genome Canada, in partnership with the Government of Canada, is proud to support collaboration between research institutions and industry that will have transformative impacts on the lives of Canadians."Dr. Rob Annan, President and CEO, Genome Canada

Quick facts

Associated links

For Canadian Science news, follow @CDNScienceon social media: Twitter, Instagram, FacebookFollow Innovation, Science and Economic Development Canada on Twitter: @ISED_CAFollow Stem Cell Network on Twitter: @StemCellNetworkFollow Genome Canada on Twitter: @GenomeCanada

SOURCE Innovation, Science and Economic Development Canada

View original content: http://www.newswire.ca/en/releases/archive/October2020/26/c7617.html

Originally posted here:
Government of Canada invests in regenerative medicine, genomics research to support Canadians' health - Benzinga

BOSTONandLONDON, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics(Nasdaq: ORTX), a global gene therapy leader, today announced that the companys chief executive officer, Bobby Gaspar, M.D., Ph.D., has been appointed to the Alliance for Regenerative Medicines (ARM) 2021 board of directors. In collaboration with the executive committee and board of directors, Dr. Gaspar will provide guidance supporting formation and implementation of ARMs strategic priorities and focus areas over the coming year.

I am honored to join the Alliance for Regenerative Medicines board at this pivotal time for cell and gene therapies, said Bobby Gaspar, CEO of Orchard. As more one-time, potentially curative medicines move toward commercialization, its imperative that we work together to meet the needs and challenges of a society accustomed to using chronic therapies to treat diseases. I look forward to collaborating with industry peers toward our common goal of bringing innovative treatment options to patients and families.

ARM is the leading international multi-stakeholder advocacy organization for the cell and gene therapy sector, promoting legislative, regulatory, and reimbursement initiatives to facilitate access to life-giving advances in regenerative medicine worldwide.

We are pleased to welcome Bobby Gaspar as one of the accomplished executives joining the 2021 ARM board of directors, said Janet Lambert, CEO of ARM. As scientists, commercial leaders, and regulatory experts, the new members of the board will be instrumental in helping ARM and its members deliver transformative and potentially curative cell and gene therapies to patients around the world.

About OrchardOrchard Therapeutics is a global gene therapy leader dedicated to transforming the lives of people affected by rare diseases through the development of innovative, potentially curative gene therapies. Our ex vivo autologous gene therapy approach harnesses the power of genetically modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. In 2018, Orchard acquired GSKs rare disease gene therapy portfolio, which originated from a pioneering collaboration between GSK and theSan Raffaele Telethon Institute for Gene Therapy in Milan, Italy. Orchard now has one of the deepest and most advanced gene therapy product candidate pipelines in the industry spanning multiple therapeutic areas where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist.

Orchard has its global headquarters in London and U.S. headquarters in Boston. For more information, please visit http://www.orchard-tx.com, and follow us on Twitter and LinkedIn.

Availability of Other Information About OrchardInvestors and others should note that Orchard communicates with its investors and the public using the company website (www.orchard-tx.com), the investor relations website (ir.orchard-tx.com), and on social media (Twitter andLinkedIn), including but not limited to investor presentations and investor fact sheets,U.S. Securities and Exchange Commissionfilings, press releases, public conference calls and webcasts. The information that Orchard posts on these channels and websites could be deemed to be material information. As a result, Orchard encourages investors, the media, and others interested in Orchard to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Orchards investor relations website and may include additional social media channels. The contents of Orchards website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Forward-Looking StatementsThis press release contains certain forward-looking statements about Orchards strategy, future plans and prospects, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include express or implied statements relating to, among other things, Orchards business strategy and goals, and the therapeutic potential of Orchards product candidates, including the product candidate or candidates referred to in this release. These statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, many of which are beyond Orchards control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, these risks and uncertainties include, without limitation: the severity of the impact of the COVID-19 pandemic on Orchards business, including on clinical development and commercial programs; the risk that any one or more of Orchards product candidates, including the product candidate or candidates referred to in this release, will not be approved, successfully developed or commercialized; the risk of cessation or delay of any of Orchards ongoing or planned clinical trials; the risk that Orchard may not successfully recruit or enroll a sufficient number of patients for its clinical trials; the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical studies or clinical trials will not be replicated or will not continue in ongoing or future studies or trials involving Orchards product candidates; the delay of any of Orchards regulatory submissions; the failure to obtain marketing approval from the applicable regulatory authorities for any of Orchards product candidates or the receipt of restricted marketing approvals; and the risk of delays in Orchards ability to commercialize its product candidates, if approved. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements.

Other risks and uncertainties faced by Orchard include those identified under the heading "Risk Factors" in Orchards quarterly report on Form 10-Q for the quarter endedJune 30, 2020, as filed with theU.S. Securities and Exchange Commission(SEC), as well as subsequent filings and reports filed with theSEC. The forward-looking statements contained in this press release reflect Orchards views as of the date hereof, and Orchard does not assume and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Contacts

InvestorsRenee LeckDirector, Investor Relations+1 862-242-0764Renee.Leck@orchard-tx.com

MediaMolly CameronManager, Corporate Communications+1 978-339-3378media@orchard-tx.com

The rest is here:
Orchard Therapeutics CEO Bobby Gaspar, M.D., Ph.D., Appointed to the Alliance for Regenerative Medicine's 2021 Board of Directors - GlobeNewswire

Market Study Report LLC adds a latest research study on Regenerative Medicine market Statistics for 2020-2026, which is a detailed analysis of this business space inclusive of trends, competitive landscape, and the market size. Encompassing one or more parameters among product analysis, application potential, and the regional growth landscape, Regenerative Medicine market also includes an in-depth study of the industry's competitive scenario.

The latest research report of the Regenerative Medicine market provides a comprehensive assessment of the key factors driving the industry growth. The study lists out the existing challenges and opportunities crucial to business expansion in the upcoming years. It also houses an economy-wide database to enhance business management and boasts of a dedicated section for profiling leading players. In addition, impact assessment of the COVID-19 pandemic is covered as well.

Request a sample Report of Regenerative Medicine Market at:https://www.marketstudyreport.com/request-a-sample/2957730?utm_source=decresearch.com&utm_medium=AK

Main pointers from the COVDI-19 impact analysis:

Additional highlights of the Regenerative Medicine market report:

Ask for Discount on Regenerative Medicine Market Report at:https://www.marketstudyreport.com/check-for-discount/2957730?utm_source=decresearch.com&utm_medium=AK

An outline of the regional analysis:

Comprehensive assessment of all opportunities and risks in the Regenerative Medicine market.

This exclusive study addresses key questions for stakeholders in the Regenerative Medicine Market:

For More Details On this Report: https://www.marketstudyreport.com/reports/global-regenerative-medicine-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread

Related Reports:

1. Global Albumin Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based on 2020 COVID-19 Worldwide Spread)Read More: https://www.marketstudyreport.com/reports/global-albumin-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread

2. Global Dental Supplies Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based on 2020 COVID-19 Worldwide Spread)Read More: https://www.marketstudyreport.com/reports/global-dental-supplies-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread

Read More Reports On: https://www.marketwatch.com/press-release/automotive-glazing-market-growth-size-share-demand-trends-and-forecasts-to-2027-2020-10-08

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

More:
Regenerative Medicine Market by Type, Application, Element - Global Trends and Forecast to 2026 - News by Decresearch

The Global Regenerative Medicine Market research report is a comprehensive study of the Regenerative Medicine industry and its prospects. The global Regenerative Medicine Market was valued at US$ 13.56 Mn in 2018 and is expected to reach US$ 55.67 Mn Mn by 2026, expanding at a CAGR of 23% during the forecast period.

The global Regenerative Medicine market has been subjected to several regulatory compliances and crucial coding terminology over the years. Adherence to regulatory standards remains crucial for vendors.

The study considers the present scenario of the Regenerative Medicine market and its market dynamics for the period 20202026. It covers a detailed overview of several market growth enablers, restraints, and trends. The report covers both the demand and supply aspect of the market. This research report on the Regenerative Medicine market covers sizing and forecast, market share, industry trends, growth drivers, and vendor analysis.

Browse Full Research report along with TOC, Tables & Figures: https://www.alltheresearch.com/report/232/Regenerative Medicine

The study profiles and examines leading companies and other prominent companies operating in the Regenerative Medicine industry.

List of key players profiled in the report:

Regenerative Medicine Market segmentation as per below:

Product Types:

Applications:

Request for Sample Copy of Report to get more information about the market @ https://www.alltheresearch.com/sample-request/232

COVID-19 Impact on Regenerative Medicine Industry

The outbreak of COVID-19 has bought along a global recession, which has impacted several industries. Along with this impact COVID Pandemic has also generated few new business opportunities for Regenerative Medicine market. Overall competitive landscape and market dynamics of Regenerative Medicine has been disrupted due to this pandemic. All these disruptions and impacts has been analysed quantifiably in this report, which is backed by market trends, events and revenue shift analysis. COVID impact analysis also covers strategic adjustments for Tier 1, 2 and 3 players of Regenerative Medicine market.

The competitive environment in the Regenerative Medicine market is intensifying. The market currently witnesses the presence of several major as well as other prominent vendors, contributing toward the market growth. However, the market is observing an influx of local vendors entering the market.

Request COVID19 Impact Analysis on Regenerative Medicine Industry Sample Report @ https://www.alltheresearch.com/impactC19-request/232

Vendors can consider targeting key regions such as APAC, North America, and Europe to gather maximum customer attention. Countries in the APAC region such as China, India, and Japan among others are expected to display significant growth prospects in the future due to high economic growth forecasts along with huge population statistics leading to high consumption of goods and products.

Regional Overview & Analysis of Regenerative Medicine Market:

North America(US and Canada)

Europe(UK, Germany, France and Rest of Europe)

Asia Pacific(China, Japan, India and Rest of Asia Pacific)

Latin America(Brazil, Mexico and Rest of Latin America)

Middle East & Africa(GCC and Rest of Middle East & Africa)

The changing regulatory compliance scenario and the growing purchasing power among consumers are likely to promise well for the North America market. New product development and technological advancements remain key for competitors to capitalize upon in the Regenerative Medicine industry across the globe.

Report Snapshot:

Report Coverage

Details

Base Year:

2018

Historical Data for:

2014 to 2018

Forecast Period:

2020 to2026

Market Size in 2018:

USD 13.56 Mn

Forecast Period 2020 to 2026 CAGR:

23%

2026 Value Projection:

USD 55.67 Mn

Ask for more details or request custom reports from our industry experts at @ https://www.alltheresearch.com/customization/232

Key Market Insights:

Read this article:
Regenerative Medicine Market Analysis and In-depth Research on Size, Trends, Emerging Growth Factors and Forecasts 2026 - PRnews Leader

What is Adipose Tissue Derived Stem Cell Therapy?

Adipose tissue derived stem cells (ADSCs) are stem cells originated from adipocytes. ADSCs have characteristics similar to bone marrow mesenchymal stem cells. Thus Adipose-derived stem cells substitute for bone marrow as a source of stem cells. Different varieties of manual and automatic stem cell separation procedures are used to separate adipose stem cells (ASCs) from adipose tissue. Flow cytometry can be utilized to isolate ADSCs from other stem cells within a cell solution. Currently, adipose derived stem cells (ADSCs) are generally used in the generation of regenerative medicine due to its anti-inflammatory, anti-apoptotic, and immunomodulatory properties.

Download PDF Sample Report Here @ https://www.theinsightpartners.com/sample/TIPRE00014843/

The research provides answers to the following key questions:

A new market study report by The Insight Partners on the Adipose Tissue Derived Stem Cell Therapy Market has been released with reliable information and accurate forecasts for a better understanding of the current and future market scenarios. The report offers an in-depth analysis of the global market, including qualitative and quantitative insights, historical data, and estimated projections about the market size and share in the forecast period. The forecasts mentioned in the report have been acquired by using proven research assumptions and methodologies. Hence, this research study serves as an important depository of the information for every market landscape. The report is segmented on the basis of types, end-users, applications, and regional markets. Some of the key players in the study are AlloCure, Inc, Antria, Inc., Celgene Corporation, Cellleris SA, Corestem, Inc., Cytori Therapeutics, LLC, Intrexon, Inc., Mesoblast Ltd., Pluristem Therapeutics, Inc., Tissue Genesis, Inc. etc.

Market Insights:

The Adipose Tissue-derived Stem Cell Therapy Market is growing due to increasing use of regenerative medicine in disease treatment and increasing private and public funding for stem cell therapy. However, high cost associated with stem cell processing hampers growth of this market.

An Overview of the Impact of COVID-19 on this Market:

Due to the pandemic, we have included a special section on the Impact of COVID 19 on the Adipose Tissue Derived Stem Cell Therapy Market which would mention How the Covid-19 is Affecting the Adipose Tissue Derived Stem Cell Therapy Industry, Market Trends and Potential Opportunities in the COVID-19 Landscape, Covid-19 Impact on Key Regions and Proposal for Adipose Tissue Derived Stem Cell Therapy Players to fight Covid-19 Impact.

Adipose Tissue Derived Stem Cell Therapy Market: Regional analysis includes:

The Adipose Tissue Derived Stem Cell Therapy Market segments and Market Data Break Down are illuminated below:By Cell Type (Autologous Stem Cells, Allogeneic Stem Cells);

Product (Cell Line, Culture Media);

Disease (Cancer, Obesity, Wounds and Injuries, Musculoskeletal Diseases, Cardiovascular Diseases, Others);

End User (Hospitals and Trauma Centers, Cell banks and Tissue Banks, Research Laboratories and Academic Institutes, Others)

The study conducts SWOT analysis to evaluate strengths and weaknesses of the key players in the Adipose Tissue Derived Stem Cell Therapy market. Further, the report conducts an intricate examination of drivers and restraints operating in the market. The report also evaluates the trends observed in the parent market, along with the macro-economic indicators, prevailing factors, and market appeal with regard to different segments. The report predicts the influence of different industry aspects on the Adipose Tissue Derived Stem Cell Therapy market segments and regions.

This report strategically examines the micro-markets and sheds light on the impact of technology upgrades on the performance of the Adipose Tissue Derived Stem Cell Therapy market.

Are you a Start-up willing to make it Big in the Business? Grab an Exclusive PDF Brochure @ https://www.theinsightpartners.com/buy/TIPRE00014843/

Note: Access insightful study with over 150+ pages, list of tables & figures, profiling 10+ companies.

Thanks for reading this article; you can also customize this report to get select chapters or region-wise coverage with regions such as Asia, North America, and Europe.

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are committed to provide highest quality research and consulting services to our customers. We help our clients understand the key market trends, identify opportunities, and make informed decisions with our market research offerings at an affordable cost.

We understand syndicated reports may not meet precise research requirements of all our clients. We offer our clients multiple ways to customize research as per their specific needs and budget

Contact Us:

The Insight Partners,

Phone: +1-646-491-9876

Email: [emailprotected]

Link:
Adipose Tissue Derived Stem Cell Therapy Market to Set Phenomenal Growth in Key Regions by 2027 | AlloCure, Inc, Antria, Inc., Cellleris SA, Tissue...

SAN DIEGO, Oct. 27, 2020 /PRNewswire/ -- Dr. Sean M. Anderson, founder of Aqua Regenerative Therapies and the scientist behind the creation of the world's first and only brain regenerating biomaterial at UCLA, has launched a patented skin care product under the brand name NeuLuna. Focusing his expertise on the skin, Dr. Anderson formulated a skin cream that improves skin adsorption of hyaluronic acid by 250%.

Sold online at neuluna.com, NeuLuna leads to softer, smoother skin in a matter of days. Customers have reported that the product helps with acne and acne scars, eye bags and wrinkles, dry skin, hands, and elbows, sun spots, rosacea, and eczema.

"It helps keep my skin firm and smooth, and even helps heal some nicks and scratches faster. It also helps prevent acne, from what I have noticed. My skin has never felt smoother and better. I highly recommend this product!" said customer Hazel F.

"The product is truly unique in the skin care space. With an issued patent covering the core technology of the product, this product is not available anywhere else. And we hope this helps us achieve our goal of funding our regenerative medicine research," said Dr. Anderson.

Sales from the skin care product directly fund Dr. Anderson's research. Currently, his interests center on developing treatments for stroke, traumatic brain and spinal cord injury, heart disease, pulmonary disease, wound healing, and diabetes, particularly diabetic neuropathy. More information can be found at aquabiomaterials.com.

Contact Dr. Sean M. Anderson at [emailprotected] for more information.

SOURCE Aqua Regenerative Therapies

https://www.aquabiomaterials.com

Link:
Creator of Brain Regenerating Biomaterial Launches Patented Skin Care Product - PRNewswire

Regenerative Medicine Market report would come handy to understand the competitors in the market and give an insight into sales, volumes, revenues in the Regenerative Medicine Industry & will also assists in making strategic decisions. The report also helps to decide corporate product & marketing strategies. It reduces the risks involved in making decisions as well as strategies for companies and individuals interested in the Regenerative Medicine industry. Both established and new players in Regenerative Medicine industries can use the report to understand the Regenerative Medicine market.

In Global Market, the Following Companies Are Covered:

Get a Sample Copy of the Report @ https://www.360marketupdates.com/enquiry/request-sample/14857372

Analysis of the Market:

Regenerative medicine is a branch of translational research in tissue engineering and molecular biology which deals with the process of replacing, engineering or regenerating human cells, tissues or organs to restore or establish normal function. It is through the use of innovative medical means rebuilding diseased or damaged tissue or to support diseased or damaged tissue regeneration. The methods used include cell therapy, tissue engineering, chemically induced and therapeutic cloning, etc. Any combination of these technologies may be used to harness or stimulate the bodys innate healing ability in order to treat a wide range of ailments, including musculoskeletal-related conditions, cardio- and peripheral vascular diseases, neurological disorders, stroke, non-healing wounds and ocular diseases.

Currently, some companies in the world can provide regenerative medicine service, mainly concentrating in USA. The main market players are DePuy Synthes, Medtronic, ZimmerBiomet, Stryker, Acelity, MiMedx Group, Organogenesis, UniQure, Cellular Dynamics International, etc.

USA is the largest market of regenerative medicine, which occupies 51.09 percent of global regenerative medicine market share in 2015. It is followed by EU, which has around 16.66 percent of the global total industry. Other main regions which take important part in this industry include Japan and China.

According to the research, the most potential market in the main countries of regenerative medicine industry is Asia, determined by the rising level of medical care. Besides, South America, Middle East should also be focused by the investors. They are the potential consumers of regenerative medicine.

Despite the presence of competition problems, due to the huge industry profits, investors are still optimistic about this area; there will be more investments to enter the field.

The relatively-mature technology is cell transplantation; tissue engineering and therapeutic cloning has its technical advantages, which is the direction of future research and development.

Market Analysis and Insights: Global Regenerative Medicine Market

In 2019, the global Regenerative Medicine market size was USUSD 8298.8 million and it is expected to reach USUSD 36710 million by the end of 2026, with a CAGR of 23.4% during 2021-2026.

Global Regenerative Medicine Scope and Market Size

Regenerative Medicine market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Regenerative Medicine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

Segment by Type, the Regenerative Medicine market is segmented into Cell Therapy, Tissue Engineering, Biomaterial, Other, etc.

Segment by Application, the Regenerative Medicine market is segmented into Dermatology, Cardiovascular, CNS, Orthopedic, Others, etc.

Regional and Country-level Analysis

The Regenerative Medicine market is analysed and market size information is provided by regions (countries).

The key regions covered in the Regenerative Medicine market report are North America, Europe, China, Japan, Southeast Asia, India and Central & South America, etc.

The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of revenue for the period 2015-2026.

Competitive Landscape and Regenerative Medicine Market Share Analysis

Regenerative Medicine market competitive landscape provides details and data information by vendors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by player for the period 2015-2020. Details included are company description, major business, company total revenue and the revenue generated in Regenerative Medicine business, the date to enter into the Regenerative Medicine market, Regenerative Medicine product introduction, recent developments, etc.

The major vendors include DePuy Synthes, Medtronic, ZimmerBiomet, Stryker, Acelity, MiMedx Group, Organogenesis, UniQure, Cellular Dynamics International, Osiris Therapeutics, Vcanbio, Gamida Cell, Golden Meditech, Cytori, Celgene, Vericel Corporation, Guanhao Biotech, Mesoblast, Stemcell Technologies, Bellicum Pharmaceuticals, etc.

This report focuses on the global Regenerative Medicine status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Regenerative Medicine development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

Regenerative Medicine Market Breakdown by Types:

s

Regenerative Medicine Market Breakdown by Application:

Critical highlights covered in the Global Regenerative Medicine market include:

The information available in the Regenerative Medicine Market report is segmented for proper understanding. The Table of contents contains Market outline, Market characteristics, Market segmentation analysis, Market sizing, customer landscape & Regional landscape. For further improving the understand ability various exhibits (Tabular Data & Pie Charts) has also been used in the Regenerative Medicine Market report.

Get a Sample Copy of the Report @ https://www.360marketupdates.com/enquiry/request-sample/14857372

Reasons for Buy Regenerative Medicine Market Report:

In the end, Regenerative Medicine Industry report provides the main region, market conditions with the product price,profit, capacity, production, supply, demand and market growth rateand forecast etc. This report also Present newproject SWOT analysis,investment feasibility analysis, andinvestment return analysis.

Contact Us:

Name: Mr. Ajay More

Email: [emailprotected]

Organization: 360 Market Updates

Phone: +14242530807 / + 44 20 3239 8187

Global Konjac Gum Market 2020 Industry Analysis, Size, Share, Trends, Market Demand, Growth, Opportunities and Showing Impressive Growth by 2026

Global MEMS G Meter Market 2020 Segmentation and Analysis by Recent Trends, consumption by Regional data, Development, Investigation, Showing Impressive Growth by 2024

Blockchain Market Size, News andlargeGrowth With Regional Trends By Forecast 2026 Research Reportwith the guide of360marketupdates

Global Algae Feed Market Size in 2020 Industry Demand, Market Share, Trend, Industry News, Business Growth, Top Key Players, Showing Impressive Growth by 2026

Account Based Market Size, Growth Opportunities, Emerging Technologies, Trends,Growth, Segments, Landscape and Research Reportwith the guide of360marketupdates

See the article here:
Regenerative Medicine Market anticipates revenue will hit up to XX% CAGR by 2026: Covering Market Share, Market Segmentation (by Major Players, Type,...

New York, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "North America Amniotic Membrane Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Enzyme ; Application ; End User, Country" - https://www.reportlinker.com/p05978887/?utm_source=GNW However, limitations encountered while using amniotic membranes in emerging nations are expected to obstruct the growth of the market to a certain extent during the forecast years.

The amniotic membrane is the innermost fetal layer, lining the amniotic cavity and protecting the fetus during pregnancy.The outer layer, termed chorionic membrane, further separates the fetus from maternal tissues.

Various researches focusing on the physiological functions of fetal layers have shown that amniotic membrane not only provides physical support for the fetus but also serves as a metabolically active filter through direct interaction with amniotic fluid. The translucent, avascular, low immunogenic, anti-inflammatory, anti-scarring, and wound healing properties of amniotic membrane allow this material function beyond its role in vivo and assume a wide range of applications in regenerative medicine.

The clinical use of amniotic membrane has a long history, with the first reports on its application in the treatment of skin burns and wounds more than a century ago.These ground-breaking studies played a significant role in advancing the use of an amniotic membrane in surgery, especially in areas such as the reconstruction of the corneal and conjunctival surfaces, treatment of open ulcers and traumatic wounds, and skin transplantation.

In parallel, the shelf life of the amniotic membrane has been extended by irradiation, air-drying, lyophilization, cryo-preservation, and glycerol preservation techniques. These methods are expected to further expand the use of an amniotic membrane in ophthalmology to treat corneal, conjunctival and limbal lesions, burns, scars and defects as well as general surgery to reconstruct the skin, genitourinary tract and other surfaces.

Amniotic membranes also appear to have natural protective and reparative functions; they may also be used for efficient delivery of specific factors to enhance the protection or repair of damaged tissue through genetic modification.

Based on enzyme, the amniotic membrane market, by enzyme, is segmented into cryopreserved amniotic membrane, and dehydrated amniotic membrane. The cryopreserved amniotic membrane segment held the largest share of the market in 2019, whereas the dehydrated amniotic membrane segment is anticipated to register the highest CAGR in the market during the forecast period.

Based on application, the amniotic membrane market, by application, is segmented into surgical wounds, ophthalmology, and others. The surgical wounds segment held the largest share of the market in 2019, also the segment is anticipated to register the highest CAGR in the market during the forecast period...Based on end-user, the amniotic membrane market is segmented into hospitals, ambulatory surgical centers, specialty clinics, research institute and academic institutes.The hospitals segment held the largest share of the market in 2019.

Moreover, the ambulatory surgical centers segment is estimated to register the highest CAGR in the market during the forecast period.

Some of the major primary and secondary sources for amniotic membranes market included in the report are American Society of Plastic Surgeons, Beckers Healthcare report, and others.Read the full report: https://www.reportlinker.com/p05978887/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Continued here:
The Amniotic membrane market is expected to reach US$ 1175.2million in 2027 from US$ 667.4million in 2019 - GlobeNewswire

Provost Professor Scott Fraser is recognized for developing technology that provides unprecedented views of live organisms, from embryonic development to old age. [3 min read]

Provost Professor Scott Fraser, a recognized innovator whose inventions have found wide use in both scientific and clinical settings, is an elected member of the National Academy of Medicine. (Photo: No Montes.)

Scott Fraser, Provost Professor of Biological Sciences, Biomedical Engineering, Physiology and Biophysics, Stem Cell Biology and Regenerative Medicine, Pediatrics, Radiology and Ophthalmology, has been elected to the National Academy of Medicine.

Fraser, who holds joint appointments at the USC Dornsife College of Letters, Arts and Sciences and USC Viterbi School of Engineering as well as the Elizabeth Garrett Chair in Convergent Bioscience, is one of just 90 researchers chosen from among the worlds leading scientists to become members of the academy.

Professor Scott E. Fraser is a brilliant biophysicist and innovator, said USC Provost Charles F. Zukoski. He is being recognized for groundbreaking advancements in biology and medicine. His research, which centers on imaging and molecular analyses of intact biological systems, serves as inspiration for future generations of engineers, scientists and medical professionals.

Among the reasons for his election, the academy noted Frasers work integrating biophysics, quantitative biology, and molecular imaging to enable unprecedented views of normal function and disease in live organisms, from embryonic development to old age.

Ive always been fascinated by interdisciplinary teams that can bring new insights into old problems by combining the insights from science, engineering and medicine, Fraser said.

Applying tricks from other fields

Fraser, who earned his bachelors degree in physics and his Ph.D. in biophysics, says he gravitated toward research in biology because there are so many open questions, and so many things that have been thought to be impossible to answer but tricks from other fields make the impossible possible, if the team is willing to tackle it together.

Frasers research delves into early development, organogenesis (the process by which internal organs emerge and develop) and medical diagnostics. His work has spawned several start-up companies and has been used in a number of instruments and FDA-approved diagnostics.

We keep our eyes open to translation of the work in the lab to industrial and clinical utility, he said, adding that USCs Alfred E. Mann Institute for Biomedical Engineering and USC Viterbis National Science Foundation-funded Innovation Corps node have both played key roles and offered important instruction on how to best bring their work to potential customers.

In the last year, our IP (intellectual property) has been licensed by a half-dozen different companies, he said. So, we know the work can lead to new instruments, new diagnostics and new techniques.

Fraser said his team works diligently to ensure collaborators in scientific and clinical fields also benefit from their efforts.

We have built the Translational Imaging Center on the University Park campus and the Translational Biomedical Imaging Center at Childrens Hospital Los Angeles to help support users with interests in fields ranging from regenerative medicine to cancer and diabetes. This is already empowering them to make new insights into their research challenges.

What we hope to do is to make it possible for researchers and clinicians to have aha moments, when they can see things for the first time.

A career highlighted by innovation

After earning his Ph.D. in 1979, Fraser joined the faculty at the University of California, Irvine, where he rose through the ranks to become chair of the Department of Physiology and Biophysics. In 1990, he moved to Caltech to serve as the Anna L. Rosen Professor of Biology and the director of the Biological Imaging Center. There, he served as the founding director of both the Caltech Brain Imaging Center and the Rosen Center for Biological Engineering and helped found the Kavli Nanoscience Institute.

In Fall 2012, Fraser moved to USC as Provost Professor at USC Dornsife and USC Viterbi, with formal links to Childrens Hospital Los Angeles and Keck School of Medicine of USC. He serves as the director of science initiatives for USC as well as co-director of the Bridge Institute at the USC Michelson Center for Convergent Bioscience.

A prolific author and inventor, Fraser has more than 240 peer-reviewed articles and more than 75 issued patents to his credit. He is the recipient of numerous honors and has been elected to the National Academy of Inventors, the American Institute for Medical and Biological Engineering, the American Association for the Advancement of Science, the American Academy of Arts and Sciences and the European Academy of Science.

About the National Academy of Medicine

The National Academy of Medicine, established in 1970 as the Institute of Medicine, is an independent organization of professionals from diverse fields including health and medicine, and the natural, social and behavioral sciences. Election to the academy recognizes individuals who have demonstrated outstanding professional achievement and commitment to service.

See the original post:
USC biological imaging innovator elected to National Academy of Medicine > News > USC Dornsife - USC Dornsife College of Letters, Arts and...

The report also provides an in-depth analysis of the competitive landscape and behavior of market participants. In this way, market participants can familiarize themselves with the current and future competitive scenario of the global market for Orthopedic Regenerative Medicine and take strategic initiatives to gain a competitive advantage. The market analysts have carried out extensive studies using research methods such as PESTLE and Porters Five Forces analysis. Overall, this report can prove to be a useful tool for market participants to gain deep insight into the global market for Orthopedic Regenerative Medicine and to understand the main perspectives and ways to increase their profit margins.

Free Sample Report + All Related Graphs & Charts @: https://www.coherentmarketinsights.com/insight/request-sample/3566

The MAJOR COMPANIES covered in Orthopedic Regenerative Medicine are:

Curasan, Inc., Carmell Therapeutics Corporation, Anika Therapeutics, Inc., Conatus Pharmaceuticals Inc., Histogen Inc., Royal Biologics, Ortho Regenerative Technologies, Inc., Swiss Biomed Orthopaedics AG, Osiris Therapeutics, Inc., and Octane Medical Inc.

Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins. For each manufacturer covered, this report analyzes their Orthopedic Regenerative Medicine manufacturing sites, capacity, production, ex-factory price, and revenue and market share in global market.

Orthopedic Regenerative Medicine Market: Segment Analysis:

The report section contains segmentations such as application, product type and end user. These segments help determine which parts of the market will improve over others. This section analysis provides information on the most important aspects of developing certain categories better than others. It helps readers understand strategies to make solid investments. The market for Orthopedic Regenerative Medicine is segmented according to product type, applications and end users.

The end users/applications and product categories analysis:

On the basis of product, this report displays the sales volume, revenue (Million USD), product price, market share and growth rate of each type, primarily split into-

General Type

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Orthopedic Regenerative Medicine for each application, including-

Finally, the feasibility of new investment projects is assessed, and overall research conclusions are offered.

Get Up to 10-25% Discount on This Premium [emailprotected]: https://www.coherentmarketinsights.com/insight/request-discount/3566

Table of Contents

Part I Orthopedic Regenerative Medicine Industry Overview

Chapter One Orthopedic Regenerative Medicine Industry Overview

1.1 Orthopedic Regenerative Medicine Definition

1.2 Orthopedic Regenerative Medicine Classification Analysis

1.2.1 Orthopedic Regenerative Medicine Main Classification Analysis

1.2.2 Orthopedic Regenerative Medicine Main Classification Share Analysis

1.3 Orthopedic Regenerative Medicine Application Analysis

1.3.1 Orthopedic Regenerative Medicine Main Application Analysis

1.3.2 Orthopedic Regenerative Medicine Main Application Share Analysis

1.4 Orthopedic Regenerative Medicine Industry Chain Structure Analysis

1.5 Orthopedic Regenerative Medicine Industry Development Overview

1.5.1 Orthopedic Regenerative Medicine Product History Development Overview

1.5.1 Orthopedic Regenerative Medicine Product Market Development Overview

1.6 Orthopedic Regenerative Medicine Global Market Comparison Analysis

1.6.1 Orthopedic Regenerative Medicine Global Import Market Analysis

1.6.2 Orthopedic Regenerative Medicine Global Export Market Analysis

1.6.3 Orthopedic Regenerative Medicine Global Main Region Market Analysis

1.6.4 Orthopedic Regenerative Medicine Global Market Comparison Analysis

1.6.5 Orthopedic Regenerative Medicine Global Market Development Trend Analysis

Chapter Two Orthopedic Regenerative Medicine Up and Down Stream Industry Analysis

2.1 Upstream Raw Materials Analysis

2.1.1 Proportion of Manufacturing Cost

2.1.2 Manufacturing Cost Structure of Orthopedic Regenerative Medicine Analysis

2.2 Down Stream Market Analysis

2.2.1 Down Stream Market Analysis

2.2.2 Down Stream Demand Analysis

2.2.3 Down Stream Market Trend Analysis

Part II Asia Orthopedic Regenerative Medicine Industry (The Report Company Including the Below Listed But Not All)

Chapter Three Asia Orthopedic Regenerative Medicine Market Analysis

3.1 Asia Orthopedic Regenerative Medicine Product Development History

3.2 Asia Orthopedic Regenerative Medicine Competitive Landscape Analysis

3.3 Asia Orthopedic Regenerative Medicine Market Development Trend

Chapter Four 2016-2020 Asia Orthopedic Regenerative Medicine Productions Supply Sales Demand Market Status and Forecast

4.1 2016-2020 Orthopedic Regenerative Medicine Production Overview

4.2 2016-2020 Orthopedic Regenerative Medicine Production Market Share Analysis

4.3 2016-2020 Orthopedic Regenerative Medicine Demand Overview

4.4 2016-2020 Orthopedic Regenerative Medicine Supply Demand and Shortage

4.5 2016-2020 Orthopedic Regenerative Medicine Import Export Consumption

4.6 2016-2020 Orthopedic Regenerative Medicine Cost Price Production Value Gross Margin

Chapter Five Asia Orthopedic Regenerative Medicine Key Manufacturers Analysis

5.1 Company A

5.1.1 Company Profile

5.1.2 Product Picture and Specification

5.1.3 Product Application Analysis

5.1.4 Capacity Production Price Cost Production Value

5.1.5 Contact Information

5.2 Company B

5.2.1 Company Profile

5.2.2 Product Picture and Specification

5.2.3 Product Application Analysis

5.2.4 Capacity Production Price Cost Production Value

5.2.5 Contact Information

5.3 Company C

5.3.1 Company Profile

Continued

Download Free PDF Brochure:https://www.coherentmarketinsights.com/insight/request-pdf/3566

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Southeast Asia.

About Us:

Coherent Market Insightsis a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contacts Us: +1-206-701-6702Email:[emailprotected]Web:https://www.coherentmarketinsights.com/

Read more:
Orthopedic Regenerative Medicine Market Study Based on Growth, Opportunities, Constraints and Development Factors for Next 5 Years - PRnews Leader

Global Regenerative Medicine market report offers a precise outline of the market that includes many aspects of market product definition, market segmentation, analysis, key developments, and existing vendors state of the business. These Regenerative Medicine industry documents include key players and geographical markets that have adopted vital methodologies for business developments and growth. The consumer trust in precise and proper Regenerative Medicine information structures that is employed for analysis of the business Report 2020 has the aim to deliver a complete analysis of the Regenerative Medicine market. The report could assist you in coming up with worthy growth methods and additionally aware and indurate challenges.

Perpetually increasing in the market, often rise in customers demands are the notable factors of growing and developing the business. Taking thought of each segments Regenerative Medicine market report is deliberate by creating each analysis of the market conditions worldwide. Examine the restraining Regenerative Medicine segments affecting the business in the coming future has been into consideration.

Get a Sample Copy of the Report at https://www.futuristicreports.com/request-sample/84632

Impact of COVID-19 on Regenerative Medicine Market

The report also contains the effect of the ongoing worldwide pandemic, i.e., COVID-19, on the Regenerative Medicine Market and what the future holds for it. It offers an analysis of the impacts of the epidemic on the international market. The epidemic has immediately interrupted the requirement and supply series. The report also assesses the economic effect on firms and monetary markets. Futuristic Reports has accumulated advice from several delegates of this business and has engaged from the secondary and primary research to extend the customers with strategies and data to combat industry struggles throughout and after the COVID-19 pandemic.

Global Regenerative Medicine Market: Competitive Landscape

(DePuy Synthes, Medtronic, ZimmerBiomet, Stryker, Acelity, MiMedx Group, Organogenesis, UniQure, Cellular Dynamics International, Osiris Therapeutics, Vcanbio, Gamida Cell, Golden Meditech, Cytori, Celgene, Vericel Corporation, Guanhao Biotech, Mesoblast, Stemcell Technologies, Bellicum Pharmaceuticals)

Segment by Type, the Regenerative Medicine market is segmented into

Cell Therapy Tissue Engineering Biomaterial Other

Segment by Application, the Regenerative Medicine market is segmented into

Dermatology Cardiovascular CNS Orthopedic Others

To Understand How Covid-19 Impact Is Covered in This Report With additional Discount: https://www.futuristicreports.com/check-discount/84632

This report also splits the market by region:

United StatesCanadaMexicoBrazilAPACChinaJapanKorea

Key Questions Answered in The Report:

Market Report includes major TOC points1 Study Coverage1.1 Regenerative Medicine Product Introduction1.2 Market Segments1.3 Key Regenerative Medicine Manufacturers Covered: Ranking by Revenue1.4 Market by Type1.4.1 Global Regenerative Medicine Market Size Growth Rate by Type1.4.2 Measuring Smart Plug1.4.3 Regular Smart Plug1.4.4 Remote Control Smart Plug1.4.5 Other1.5 Market by Application1.5.1 Global Regenerative Medicine Market Size Growth Rate by Application1.5.2 Home1.5.3 Commercial1.6 Study Objectives1.7 Years Considered

2 Executive Summary2.1 Global Regenerative Medicine Market Size, Estimates and Forecasts2.1.1 Global Regenerative Medicine Revenue 2016-20262.1.2 Global Regenerative Medicine Sales 2016-20262.2 Global Regenerative Medicine, Market Size by Producing Regions: 2016 VS 2020 VS 20262.3 Regenerative Medicine Historical Market Size by Region (2016-2020)2.3.1 Global Regenerative Medicine Retrospective Market Scenario in Sales by Region: 2016-20202.3.2 Global Regenerative Medicine Retrospective Market Scenario in Revenue by Region: 2016-20202.4 Regenerative Medicine Market Estimates and Projections by Region (2021-2026)2.4.1 Global Regenerative Medicine Sales Forecast by Region (2021-2026)2.4.2 Global Regenerative Medicine Revenue Forecast by Region (2021-2026)

3 Global Regenerative Medicine Competitor Landscape by Players3.1 Global Top Regenerative Medicine Sales by Manufacturers3.1.1 Global Regenerative Medicine Sales by Manufacturers (2016-2020)3.1.2 Global Regenerative Medicine Sales Market Share by Manufacturers (2016-2020)3.2 Global Regenerative Medicine Manufacturers by Revenue3.2.1 Global Regenerative Medicine Revenue by Manufacturers (2016-2020)3.2.2 Global Regenerative Medicine Revenue Share by Manufacturers (2016-2020)3.2.3 Global Regenerative Medicine Market Concentration Ratio (CR5 and HHI) (2016-2020)3.2.4 Global Top 10 and Top 5 Companies by Regenerative Medicine Revenue in 20193.2.5 Global Regenerative Medicine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.3 Global Regenerative Medicine Price by Manufacturers3.4 Global Regenerative Medicine Manufacturing Base Distribution, Product Types3.4.1 Regenerative Medicine Manufacturers Manufacturing Base Distribution, Headquarters3.4.2 Manufacturers Regenerative Medicine Product Type3.4.3 Date of International Manufacturers Enter into Regenerative Medicine Market3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2016-2026)4.1 Global Regenerative Medicine Market Size by Type (2016-2020)4.1.1 Global Regenerative Medicine Sales by Type (2016-2020)4.1.2 Global Regenerative Medicine Revenue by Type (2016-2020)4.1.3 Regenerative Medicine Average Selling Price (ASP) by Type (2016-2026)4.2 Global Regenerative Medicine Market Size Forecast by Type (2021-2026)4.2.1 Global Regenerative Medicine Sales Forecast by Type (2021-2026)4.2.2 Global Regenerative Medicine Revenue Forecast by Type (2021-2026)4.2.3 Regenerative Medicine Average Selling Price (ASP) Forecast by Type (2021-2026)4.3 Global Regenerative Medicine Market Share by Price Tier (2016-2020): Low-End, Mid-Range, and High-End

5 Market Size by Application (2016-2026)5.1 Global Regenerative Medicine Market Size by Application (2016-2020)5.1.1 Global Regenerative Medicine Sales by Application (2016-2020)5.1.2 Global Regenerative Medicine Revenue by Application (2016-2020)5.1.3 Regenerative Medicine Price by Application (2016-2020)5.2 Regenerative Medicine Market Size Forecast by Application (2021-2026)5.2.1 Global Regenerative Medicine Sales Forecast by Application (2021-2026)5.2.2 Global Regenerative Medicine Revenue Forecast by Application (2021-2026)5.2.3 Global Regenerative Medicine Price Forecast by Application (2021-2026)

..Continued

Inquire or Share Your Questions If Any before the Purchasing This Report https://www.futuristicreports.com/send-an-enquiry/84632

Our Other Reports:

Global Semiconductor Photoresist Stripping Market Research Report

Global Cerebral Oximeters Market Research Report

Polyethylene Market in World Outlook, Dynamics and Forecast, Covid-19 Impact by 2026 | Futuristic Reports

Global Facial Erythema Therapies Market 2020 Competitive Landscape, Trends and Opportunities

Futuristic Reports

Name: Mark RiveraTel: +1-408-520-9037Email: [emailprotected]

Go here to read the rest:
Regenerative Medicine Market Size, Growth, Analysis Of Key- players Types And Application, Outlook, Covid-19 Impact by 2026 | Futuristic Reports - The...

In a recent clinical trial for an immune cell therapy for lymphoma, 62% of patients experienced complete cancer clearance in spite of the fact that some of them were on their 5th line of treatment. Stem cell therapies have the potential to enact more of these paradigm-shifting treatments. Proposition 14 will continue to advance these therapies and bring them to full development as available cures.

The vision of stem cell therapy is that a physician can just as easily grab an IV bag full of therapeutic cells as they might draw a drug into a syringe. Conceived through Proposition 71 in 2004, the California Institute for Regenerative Medicine (CIRM) serves as a vehicle to support all aspects of stem cell research. Medical progress requires not just well-designed clinical studies but also a well-trained workforce, educated at the intersection of stem cell biology, engineering, and chemistry.

Since 2008, CIRM has supported the training of nearly 1300 Community College and California State University students for the emerging field of Regenerative Medicine through the Bridges to Stem Cell Research and Therapy Program. The Bridges Training Program has functioned as a pathway for first-generation and underrepresented students from Humboldt to San Diego, to all of the biomedical sectors startup and cell therapy companies, academic research institutes, graduate and medical school, and more. Exposure to hands-on labs, advanced seminar discussions, and a required paid internship fully prepares these students for entering the stem cell workforce. Over 80% of Bridges alumni have either advanced to graduate school or joined the biomedical workforce in industry or academic institutions. These Programs bring a greater return than the initial cost of training.

SPONSORED

Consider Vahid Hamzeinejad, a bright high school student, headed to UC Berkeley to begin his college career. Enter the Great Recession; Vahid found himself back at home, working non-stop to help keep his parents restaurant afloat. Not giving up on his commitment to an education, he enrolled at the College of the Canyons. After completing an Associates degree, Vahid transferred to Cal Poly, hoping to join the Bridges Program. After receiving the Bridges core training, Vahid started his internship at ViaCyte, where he continues to work today, as a critical member of the team supporting ViaCytes clinical development of a functional cure for diabetes. The nearly $30 billion that California currently spends on diabetes treatments could be significantly reduced, in no small part due to the efforts of a student that cost taxpayers $36,000 to educate. That is before considering the benefit to patients quality of life that would occur by replacing insulin pumps, glucose monitors, and constant vigilance with a stem-cell-derived tissue that regulates blood sugar levels biologically making and secreting its own insulin.

Passing Proposition 14 will enable this and other unparalleled treatments for diabetes, heart disease, cancer, and neurological disorders.

Signed,

Robert Kam and the CIRM Bridges Program

SPONSORED

Continue reading here:
CIRM Bridges to Stem Cell Research & Therapy The Bridge to Everywhere (in biomedicine) OP-ED - The Silicon Valley Voice

InvestorPlace

In late September, a U.S. House vote to remove marijuana from the federal Controlled Substances Act was delayed until after the presidential election. If the House remains controlled by Democrats, industry analysts expect the Marijuana Opportunity Reinvestment and Expungement (MORE) Act to potentially pass before the end of 2020. Then, it would be up to the Senate to possibly take a similar action. Today, we will look at three marijuana stocks to buy with decriminalization in the agenda.Canada is the first and only G7 nation to have legalized cannabis nationwide. In the U.S., at the federal level, marijuana is illegal and remains a Schedule I drug. Legal status varies at the state level. However, Democratic vice president nominee Kamala Harris has recently said marijuana would be decriminalized at the federal level under a Biden administration.2018 saw excessive speculation in marijuana stocks. Yet since 2019, a wide range of issues have affected the cannabis industry. Recreational cannabis sales in Canada hit significant headwinds and never reached the levels investors hoped. Although revenue improved for some companies, they have yet to become profitable. And cash burn remains concerning. As a result, most marijuana stocks have been on a roller coaster ride and hit new lows. Put another way, the bubble has burst.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAccording to recent research led by Douglas Berman of Ohio State University, the COVID-19 pandemic has both introduced tremendous new challenges for the cannabis industry and exacerbated long-standing difficulties for businesses in this arena.7 Value Stocks to Buy in an Overvalued MarketNonetheless, with difficulties usually come new opportunities while industry leaders and innovations may appear. With that information, here are three marijuana stocks that could benefit from U.S. developments at the federal level:Constellation Brands(NYSE:STZ)ETFMG Alternative Harvest ETF(NYSEARCA:MJ)GW Pharma(NASDAQ:GWPH)Marijuana Stocks: Constellation Brands(STZ)Source: ShinoStock / Shutterstock.comConstellation Brands is best known as a leading producer and marketer of alcoholic beverages. It holds a large portfolio of beer, wine and distilled spirits brands. Several of those well-recognized brands include Corona, Modelo, Robert Mondavi, Svedka vodka, Casa Noble tequila and High West whiskey. It is one the fastest-growing large consumer packaged goods companies stateside. Outside the U.S., it has operations in Italy, Mexico and New Zealand.The Victor, New York-based group is on our list of marijuana stocks because in 2018, it took a large stake in Ontario, Canada-based Canopy Growth(NYSE:CGC), one of the leading Canadian marijuana producers. STZs 38%-stake in CGC means the latter now has considerable managerial and financial backing.So far, this equity stake in Canopy Growth has been an earnings drag for Constellation Brands, and it will likely remain so in the near future. However, any potential improvement in the outlook of the pot sector in Canada and the U.S. could easily benefit STZ stock. Therefore, this indirect play on CGC could be a less risky approach for many investors.Year-to-date, STZ stock is down about 1.5%. However, that metric tells only half the story. Since the lows hit in early spring, the stock is up about 80%. The current forward price-earnings and price-sales ratios stand at at 20.88 and 4.78 respectively. Wed look to buy the the dips in price, especially if there is a decline toward the $175 level.ETFMG Alternative Harvest ETF (MJ)Source: ShutterstockThe ETFMG Alternative Harvest ETF offers exposure to Canadian cannabis producers as well as a number of firms with exposure to the industry, albeit indirectly. Thus the fund could be appropriate for long-term investors who are interested in the pot sector, but would like to have access to a diverse range of companies.MJ, which has 37 holdings, tracks the Prime Alternative Harvest index. Canopy Growth, Cronos (NASDAQ:CRON), and Tilray (NASDAQ:TLRY) top the list of holdings. Top-10 names make up around half of net assets, which stand around $550 million. The ETF was launched in 2015.7 Value Stocks to Buy in an Overvalued MarketSo far this year, the fund is down more than 30% and hit an all-time low in March. Since 2019, MJ has lost considerable value, driven by the industrys weakness and poor earnings by most pot companies. These stocks tend to be very choppy when their quarterly earnings are due. Given the volatility in the sector, long-term investors should be ready for large short-term price fluctuations in the fund. The sector is risky, but MJs diversification makes it safer than many alternatives.GW Pharma (GWPH)Source: ShutterstockOur final marijuana stock is the cannabis-focused biotech GW Pharma. According to a recent report by the United Nations, Britain is the biggest producer and exporter of legal cannabis in the world. And almost all of the exports are in a single drug, i.e., Sativex, produced by the UK-based GW Pharma. It is used to treat spasms in multiple sclerosis patients.Earlier in the year, the U.S. Drug Enforcement Administration also descheduled Epidiolex, another one of the companys products. As a result, it is no longer listed as a controlled substance stateside. In August, the U.S. Food and Drug Administration approved it to treat seizures in tuberous sclerosis complex.GW is also one of MJs largest holding, accounting for 6.41% of its assets. GWPH stock could be an alternative way to get exposure to the cannabis industry. Year-to-date, the shares are down around 8%. A potential decline toward $90 or below would improve the safety margin for long-term investors.On the date of publication, Tezcan Gecgil did not have (either directly or indirectly) any positions in the securities mentioned in this article.TezcanGecgil has worked in investment management for over two decades in the U.S. and U.K. In addition to formal higher education in the field, she has also completed all 3 levels of the Chartered Market Technician (CMT) examination. Her passion is for options trading based on technical analysis of fundamentally strong companies. She especially enjoys setting up weekly covered calls for income generation. She also publisheseducationalarticles on long-term investing.More From InvestorPlaceForget The Election Pick These Stocks for the Win in 2021Why Everyone Is Investing in 5G All WRONGAmericas #1 Stock Picker Reveals His Next 1,000% WinnerRevolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 CompanyThe post 3 Marijuana Stocks to Buy With Decriminalization on the Table appeared first on InvestorPlace.

Read more from the original source:
Former NFL Players Show Interest in Regenerative Medicine and Cell Therapies - Yahoo Finance

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Regenerative Medicine Market.

Trusted Business Insights presents an updated and Latest Study on Regenerative Medicine Market. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Regenerative Medicine Market during the forecast period.It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Regenerative Medicine Market Size, Share and Industry Analysis By Product (Cell Therapy, Gene Therapy, Tissue Engineering, Platelet Rich Plasma), By Application (Orthopaedics, Wound Care, Oncology), By Distribution Channel (Hospitals, Clinics) & Regional Forecast, 2020 2029 (Includes COVID-19 Business Impact)

We have updated Regenerative Medicine Market with respect to COVID-19 Business Impact.Inquire before buying

This report focuses on the Regenerative Medicine market and value at the global level, regional level, and company level. From a global perspective, this report represents the overall Regenerative Medicine market size by analyzing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America.

Global Regenerative Medicine Market: Segment Analysis

The research report includes specific segments by region (country), by Company, by Type, and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2019 to 2029. An in-depth analysis of the segments assists in identifying the different factors that will aid market growth.

Global Regenerative Medicine Market: Regional Analysis

The research report includes a detailed study of regions of North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America. The report has been curated after observing and studying various factors that determine regional growth such as the economic, environmental, social, technological, and political status of the particular region. Researchers have studied the data of revenue, sales, and manufacturers of each mentioned region. This section analyses region-wise revenue and volume for the forecast period of 2019 to 2029.

Global Regenerative Medicine Market: Competitive Landscape

This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2019 to 2029.List of Companies Profiled

Report Coverage

The potential to directly alter human genes was first recognized nearly more than 50 years ago. Cell and gene therapy, represent overlapping fields of biomedical research with similar therapeutic goals. Regenerative medicine also comprises of therapeutic tissue engineering and biomaterials -engineered substances used in medical applications to supplement or replace a natural body function. The increased number of the clinical trials and the use of the regenerative medicine for the development of the medicine to treat chronic diseases are some of the factors propelling the regenerative medicine market trends.

The report provides qualitative and quantitative insights on the regenerative medicine industry trends and detailed analysis of market size and growth rate for all possible segments in the market. The market is segments include type, application, distribution channel, and geography. On the basis of the type, the market is segmented into cell therapy, gene therapy, tissue engineering and platelet rich plasma. On the basis of the application, the market is segmented into orthopedics, wound care, oncology and others. On the basis of distribution channel, the regenerative medicine market is segmented into hospitals, clinics and others. Geographically, the market is segmented into five major regions, which are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions are further categorized into countries.

Along with this, the regenerative medicine market report comprises analysis of the industry dynamics and competitive landscape. Various key insights provided in the report are prevalence and incidence of diabetes by key countries, advancements in insulin delivery devices, recent industry developments such as mergers & acquisitions, pricing analysis, technological advancements, and key industry trends.

SEGMENTATION

By Product

By Application

By Distribution Channel

By Geography

Key Industry Developments

In September 2020, Takeda Pharmaceutical Company Limited announced the expansion of its cell therapy manufacturing capabilities with the opening of a new 24,000 square-foot R&D cell therapy manufacturing facility at its R&D headquarters in Boston, Massachusetts. The facility provides end-to-end research and development capabilities and will accelerate Takedas efforts to develop next-generation cell therapies, initially focused on oncology with the potential to expand into other therapeutic areas.

The R&D cell therapy manufacturing facility will produce cell therapies for clinical evaluation from discovery through pivotal Phase 2b trials. The current Good Manufacturing Practices (cGMP) facility is designed to meet all U.S., E.U., and Japanese regulatory requirements for cell therapy manufacturing to support Takeda clinical trials around the world.

Takedas Cell Therapy Translational Engine (CTTE) connects clinical translational science, product design, development, and manufacturing through each phase of research, development, and commercialization. It provides bioengineering, chemistry, manufacturing, and control (CMC), data management, analytical, and clinical and translational capabilities in a single footprint to overcome many of the manufacturing challenges experienced in cell therapy development.

In 2018, Novartis received EU approval for one-time gene therapy Luxturna, which has been developed to restore vision in people with rare and genetically-associated retinal disease.

In 2018, Novartis received EU approval for its CAR-T cell therapy, Kymriah.In 2017, Integra LifeSciences launched its product, Integra Dermal Regeneration Template Single Layer Thin for dermal repair defects reconstruction in a one-step procedure.

 

Looking for more? Check out our repository for all available reports on Regenerative Medicine Market in related sectors.

Quick Read Table of Contents of this Report @ Regenerative Medicine Market Size, Share and Industry Analysis By Product (Cell Therapy, Gene Therapy, Tissue Engineering, Platelet Rich Plasma), By Application (Orthopaedics, Wound Care, Oncology), By Distribution Channel (Hospitals, Clinics) & Regional Forecast, 2020 2029 (Includes COVID-19 Business Impact)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

Original post:
Regenerative Medicine Market Size, Share and Industry Analysis By Product (Cell Therapy, Gene Therapy, Tissue Engineering, Platelet Rich Plasma), By...

Gosselies, Belgium, 12 October 2020, 7am CEST BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announce that CEO, Miguel Forte, MD, PhD will present at the annual Cell & Gene Meeting on the Mesa to be held virtually October 12-16. Miguel Forte will also chair the session The European Regulatory Environment for ATMPs Should we expect more or less regulation? with the participation of panelists from the European Organization for Rare Diseases (EURORDIS), the European Medicines Agency (EMA) and the European Commission.

Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Mesa is a five-day virtual conference featuring more than 120 dedicated company presentations by leading public and private companies, highlighting technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, gene editing, tissue engineering, and broader regenerative medicine technologies. The meeting also includes over 100 panelists and featured speakers taking part in 20 in-depth sessions covering all aspects of cell and gene therapy commercialization. Companies presentations will be available to view on-demand throughout the entirety of the conference

Please visit http://www.meetingonthemesa.com for full information including registration. Complimentary attendance at this event is available for credentialed investors and members of the media only. Investors should contact Laura Stringham at lstringham@alliancerm.org and interested media should contact Kaitlyn Dupont at kdupont@alliancerm.org.

About Bone Therapeutics

Bone Therapeutics is a leading biotech company focused on the development of innovative products to address high unmet needs in orthopedics and other diseases. The Company has a, diversified portfolio of cell and biologic therapies at different stages ranging from pre-clinical programs in immunomodulation to mid-to-late stage clinical development for orthopedic conditions, targeting markets with large unmet medical needs and limited innovation.

Bone Therapeutics is developing an off-the-shelf next-generation improved viscosupplement, JTA-004, which is currently in phase III development for the treatment of pain in knee osteoarthritis. Consisting of a unique combination of plasma proteins, hyaluronic acid - a natural component of knee synovial fluid, and a fast-acting analgesic, JTA-004 intends to provide added lubrication and protection to the cartilage of the arthritic joint and to alleviate osteoarthritic pain and inflammation. Positive phase IIb efficacy results in patients with knee osteoarthritis showed a statistically significant improvement in pain relief compared to a leading viscosupplement.

Bone Therapeutics core technology is based on its cutting-edge allogeneic cell therapy platform with differentiated bone marrow sourced Mesenchymal Stromal Cells (MSCs) which can be stored at the point of use in the hospital. Currently in pre-clinical development, BT-20, the most recent product candidate from this technology, targets inflammatory conditions, while the leading investigational medicinal product, ALLOB, represents a unique, proprietary approach to bone regeneration, which turns undifferentiated stromal cells from healthy donors into bone-forming cells. These cells are produced via the Bone Therapeutics scalable manufacturing process. Following the CTA approval by regulatory authorities in Europe, the Company is ready to start the phase IIb clinical trial with ALLOB in patients with difficult tibial fractures, using its optimized production process. ALLOB continues to be evaluated for other orthopedic indications including spinal fusion, osteotomy, maxillofacial and dental.

Bone Therapeutics cell therapy products are manufactured to the highest GMP standards and are protected by a broad IP (Intellectual Property) portfolio covering ten patent families as well as knowhow. The Company is based in the BioPark in Gosselies, Belgium. Further information is available at http://www.bonetherapeutics.com.

For further information, please contact:

Bone Therapeutics SAMiguel Forte, MD, PhD, Chief Executive OfficerJean-Luc Vandebroek, Chief Financial OfficerTel: +32 (0)71 12 10 00investorrelations@bonetherapeutics.com

For Belgian Media and Investor Enquiries:BepublicCatherine HaquenneTel: +32 (0)497 75 63 56catherine@bepublic.be

International Media Enquiries:Image Box CommunicationsNeil Hunter / Michelle BoxallTel: +44 (0)20 8943 4685neil.hunter@ibcomms.agency / michelle@ibcomms.agency

For French Media and Investor Enquiries:NewCap Investor Relations & Financial CommunicationsPierre Laurent, Louis-Victor Delouvrier and Arthur RouillTel: +33 (0)1 44 71 94 94bone@newcap.eu

For US Media and Investor Enquiries:LHA Investor RelationsYvonne BriggsTel: +1 310 691 7100ybriggs@lhai.com

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such persons officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Continue reading here:
Bone Therapeutics to present at 2020 Virtual Cell & Gene Meeting on the Mesa - GlobeNewswire